Symbols / XTNT $0.54 -1.81% Xtant Medical Holdings, Inc.

Healthcare • Medical Devices • United States • ASE
XTNT Chart
About

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Medical Devices Market Cap 76.02M
Enterprise Value 99.51M Income 1.75M Sales 133.08M
Book/sh 0.36 Cash/sh 0.07 Dividend Yield —
Payout 0.00% Employees 217 IPO —
P/E 54.30 Forward P/E -10.86 PEG —
P/S 0.57 P/B 1.51 P/C —
EV/EBITDA 9.13 EV/Sales 0.75 Quick Ratio 1.01
Current Ratio 2.21 Debt/Eq 64.48 LT Debt/Eq —
EPS (ttm) 0.01 EPS next Y -0.05 EPS Growth —
Revenue Growth 19.00% Earnings 2026-03-31 ROA 3.87%
ROE 3.64% ROIC — Gross Margin 62.02%
Oper. Margin 7.64% Profit Margin 1.32% Shs Outstand 140.00M
Shs Float 54.03M Short Float 0.02% Short Ratio 0.25
Short Interest — 52W High 0.95 52W Low 0.34
Beta -0.17 Avg Volume 149.89K Volume 164.70K
Target Price $1.35 Recom Strong_buy Prev Close $0.55
Price $0.54 Change -1.81%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.35
Mean price target
2. Current target
$0.54
Latest analyst target
3. DCF / Fair value
$1.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.54
Low
$1.20
High
$1.50
Mean
$1.35

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-11 main BTIG Buy → Buy $2
2024-05-16 main BTIG Buy → Buy $3
2023-12-05 init BTIG — → Buy $2
2023-07-11 main Craig-Hallum Buy → Buy $1
2023-04-26 init Craig-Hallum — → Buy $1
2019-05-17 down Maxim Group Buy → Hold —
2016-12-08 init Maxim Group — → Buy $2
2016-11-30 init Aegis Capital — → Buy $4
News
RSS: Latest XTNT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-14 BAKEWELL JOHN K Director — 158,228 $0.00 $0
2025-11-14 BAKEWELL JOHN K Director — 158,228 $0.00 $0
2025-11-14 LIPSCHULTZ TYLER P Director — 158,228 $0.00 $0
2025-11-14 VIZIRGIANAKIS STAVROS G Director — 553,797 $0.00 $0
2025-11-14 BROWNE SEAN E. Chief Executive Officer — 394,937 $0.00 $0
2025-11-14 NEILS SCOTT C Chief Financial Officer — 263,291 $0.00 $0
2025-11-14 SCHALLENBERGER MARK A. Chief Operating Officer — 292,253 $0.00 $0
2025-11-14 BEESON JONN R. Director — 158,228 $0.00 $0
2025-11-14 JAIN ABHINAV Director — 158,228 $0.00 $0
2025-04-10 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 73,114,592 $0.42 $30,708,129
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
117.27
+28.44%
91.30
+57.50%
57.97
+4.90%
55.26
Operating Revenue
117.27
+28.44%
91.30
+57.50%
57.97
+5.12%
55.15
Cost Of Revenue
49.05
+36.88%
35.84
+38.73%
25.83
+13.43%
22.77
Reconciled Cost Of Revenue
49.05
+36.88%
35.84
+38.73%
25.83
+13.43%
22.77
Gross Profit
68.22
+22.98%
55.47
+72.60%
32.14
-1.09%
32.49
Operating Expense
80.29
+22.35%
65.62
+68.74%
38.89
+7.01%
36.34
Research And Development
2.38
+78.52%
1.34
+46.01%
0.92
+5.17%
0.87
Selling General And Administration
77.91
+21.18%
64.29
+69.28%
37.98
+7.06%
35.47
Selling And Marketing Expense
49.21
+28.03%
38.44
+70.73%
22.52
+7.09%
21.02
General And Administrative Expense
28.69
+10.99%
25.85
+67.18%
15.46
+7.01%
14.45
Other Gand A
28.69
+10.99%
25.85
+67.18%
15.46
+7.01%
14.45
Total Expenses
129.34
+27.48%
101.46
+56.76%
64.72
+9.48%
59.12
Operating Income
-12.07
-18.86%
-10.16
-50.38%
-6.75
-75.27%
-3.85
Total Operating Income As Reported
-12.07
-18.86%
-10.16
-50.38%
-6.75
-75.27%
-3.85
EBITDA
-7.88
-255.23%
5.08
+193.43%
-5.43
-115.38%
-2.52
Normalized EBITDA
-7.88
-14.51%
-6.88
-26.73%
-5.43
-115.38%
-2.52
Reconciled Depreciation
4.22
+33.08%
3.17
+145.67%
1.29
-3.00%
1.33
EBIT
-12.10
-736.61%
1.90
+128.27%
-6.72
-74.47%
-3.85
Total Unusual Items
0.01
-99.96%
11.96
0.00
—
Total Unusual Items Excluding Goodwill
0.01
-99.96%
11.96
0.00
—
Special Income Charges
0.00
-100.00%
11.69
0.00
—
Restructuring And Mergern Acquisition
0.00
+100.00%
-11.69
0.00
—
Net Income
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Pretax Income
-16.26
-1468.18%
-1.04
+87.68%
-8.42
-73.56%
-4.85
Net Non Operating Interest Income Expense
-4.16
-49.16%
-2.79
-67.91%
-1.66
-66.93%
-0.99
Interest Expense Non Operating
4.16
+41.59%
2.94
+73.64%
1.69
+70.05%
0.99
Net Interest Income
-4.16
-49.16%
-2.79
-67.91%
-1.66
-66.93%
-0.99
Interest Expense
4.16
+41.59%
2.94
+73.64%
1.69
+70.05%
0.99
Interest Income Non Operating
0.00
-100.00%
0.15
+380.65%
0.03
0.00
Interest Income
0.00
-100.00%
0.15
+380.65%
0.03
0.00
Other Income Expense
-0.03
-100.24%
11.91
—
—
Other Non Operating Income Expenses
-0.03
+32.65%
-0.05
—
—
Gain On Sale Of Security
0.01
-98.11%
0.27
—
—
Tax Provision
0.19
+111.02%
-1.70
-2559.42%
0.07
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
-99.96%
2.51
0.00
0.00
Net Income Including Noncontrolling Interests
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Net Income From Continuing Operation Net Minority Interest
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Net Income From Continuing And Discontinued Operation
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Net Income Continuous Operations
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Normalized Income
-16.45
-87.23%
-8.79
-3.57%
-8.48
-74.98%
-4.85
Net Income Common Stockholders
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Diluted EPS
-0.12
-1300.00%
0.01
+111.11%
-0.09
-50.00%
-0.06
Basic EPS
-0.12
-1300.00%
0.01
+111.11%
-0.09
-50.00%
-0.06
Basic Average Shares
133.67
+12.24%
119.09
+26.58%
94.09
+10.10%
85.46
Diluted Average Shares
133.67
+5.42%
126.79
+34.76%
94.09
+10.10%
85.46
Diluted NI Availto Com Stockholders
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
93.84
+1.32%
92.61
+53.77%
60.23
+10.12%
54.69
Current Assets
67.12
+3.46%
64.87
+31.53%
49.32
+11.25%
44.33
Cash Cash Equivalents And Short Term Investments
6.20
+8.47%
5.71
-71.84%
20.30
+11.26%
18.24
Cash And Cash Equivalents
6.20
+8.47%
5.71
-71.84%
20.30
+11.26%
18.24
Receivables
20.66
-0.34%
20.73
+91.02%
10.85
+51.71%
7.15
Accounts Receivable
20.66
-0.34%
20.73
+91.02%
10.85
+51.71%
7.15
Gross Accounts Receivable
22.10
+2.06%
21.65
+90.46%
11.37
+47.52%
7.71
Allowance For Doubtful Accounts Receivable
-1.44
-56.20%
-0.92
-78.64%
-0.52
+6.70%
-0.55
Inventory
38.63
+4.74%
36.88
+113.39%
17.29
-3.68%
17.95
Raw Materials
6.62
-8.90%
7.27
+29.16%
5.63
+0.27%
5.61
Work In Process
2.81
+80.03%
1.56
+95.74%
0.80
+39.75%
0.57
Finished Goods
29.20
+4.08%
28.05
+158.35%
10.86
-7.67%
11.76
Prepaid Assets
—
—
—
0.84
Restricted Cash
0.02
-89.42%
0.21
-0.48%
0.21
+45.14%
0.14
Other Current Assets
1.60
+20.38%
1.33
+97.62%
0.67
-20.26%
0.84
Total Non Current Assets
26.72
-3.68%
27.74
+154.27%
10.91
+5.30%
10.36
Net PPE
10.96
+7.29%
10.21
+42.57%
7.17
+10.74%
6.47
Gross PPE
30.80
+3.02%
29.89
+18.97%
25.13
+6.30%
23.64
Accumulated Depreciation
-19.84
-0.80%
-19.68
-9.55%
-17.96
-4.63%
-17.17
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.61
+3.53%
1.56
+22.55%
1.27
+2.58%
1.24
Other Properties
24.83
+3.49%
23.99
+21.45%
19.75
+6.48%
18.55
Leases
4.36
+0.21%
4.35
+5.90%
4.11
+6.65%
3.85
Goodwill And Other Intangible Assets
15.66
-9.94%
17.39
+389.91%
3.55
-1.55%
3.60
Goodwill
7.30
+0.00%
7.30
+127.83%
3.21
+0.00%
3.21
Other Intangible Assets
8.36
-17.14%
10.09
+2831.69%
0.34
-14.00%
0.40
Other Non Current Assets
0.10
-26.95%
0.14
-28.43%
0.20
-31.36%
0.29
Total Liabilities Net Minority Interest
50.87
+23.29%
41.26
+58.35%
26.06
+9.45%
23.81
Current Liabilities
28.58
+24.32%
22.99
+51.07%
15.22
+37.38%
11.08
Payables And Accrued Expenses
15.69
-10.21%
17.47
+94.45%
8.99
+29.04%
6.96
Payables
13.48
-15.44%
15.94
+100.45%
7.95
+37.16%
5.80
Accounts Payable
7.92
+12.25%
7.05
+102.12%
3.49
+33.46%
2.62
Other Payable
5.57
-37.40%
8.89
+99.15%
4.46
+40.20%
3.18
Current Accrued Expenses
2.21
+44.28%
1.53
+48.16%
1.03
-11.42%
1.17
Current Debt And Capital Lease Obligation
12.89
+133.68%
5.52
-11.47%
6.23
+51.52%
4.11
Current Debt
12.12
+162.22%
4.62
-19.08%
5.71
+57.79%
3.62
Other Current Borrowings
—
—
2.33
—
Current Capital Lease Obligation
0.77
-13.74%
0.90
+72.12%
0.52
+5.48%
0.49
Total Non Current Liabilities Net Minority Interest
22.29
+22.00%
18.27
+68.57%
10.84
-14.86%
12.73
Long Term Debt And Capital Lease Obligation
22.25
+23.33%
18.04
+66.44%
10.84
-14.86%
12.73
Long Term Debt
22.04
+28.37%
17.17
+77.22%
9.69
-17.82%
11.79
Long Term Capital Lease Obligation
0.21
-75.66%
0.88
-24.11%
1.15
+22.01%
0.94
Non Current Deferred Liabilities
0.04
+100.00%
0.02
0.00
—
Non Current Deferred Taxes Liabilities
0.04
+100.00%
0.02
0.00
—
Stockholders Equity
42.96
-16.33%
51.35
+50.27%
34.17
+10.65%
30.88
Common Stock Equity
42.96
-16.33%
51.35
+50.27%
34.17
+10.65%
30.88
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
139.05
+6.81%
130.18
+19.57%
108.87
+25.04%
87.07
Ordinary Shares Number
139.05
+6.81%
130.18
+19.57%
108.87
+25.04%
87.07
Additional Paid In Capital
302.74
+2.86%
294.33
+5.93%
277.84
+4.42%
266.07
Retained Earnings
-259.46
-6.77%
-243.01
+0.27%
-243.67
-3.61%
-235.19
Gains Losses Not Affecting Retained Earnings
-0.32
-1189.66%
0.03
0.00
—
Other Equity Adjustments
-0.32
-1189.66%
0.03
—
—
Total Equity Gross Minority Interest
42.96
-16.33%
51.35
+50.27%
34.17
+10.65%
30.88
Total Capitalization
65.00
-5.13%
68.52
+56.22%
43.86
+2.78%
42.67
Working Capital
38.53
-7.98%
41.88
+22.81%
34.10
+2.55%
33.25
Invested Capital
77.12
+5.45%
73.14
+47.54%
49.57
+7.09%
46.29
Total Debt
35.14
+49.17%
23.56
+38.00%
17.07
+1.35%
16.84
Net Debt
27.96
+73.94%
16.07
—
—
Capital Lease Obligations
0.98
-44.35%
1.77
+5.80%
1.67
+16.34%
1.44
Net Tangible Assets
27.30
-19.60%
33.96
+10.91%
30.62
+12.26%
27.28
Tangible Book Value
27.30
-19.60%
33.96
+10.91%
30.62
+12.26%
27.28
Line Of Credit
12.12
+162.22%
4.62
+36.79%
3.38
-6.66%
3.62
Non Current Accrued Expenses
0.00
-100.00%
0.21
0.00
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-11.90
-25.02%
-9.52
-78.15%
-5.34
-1316.63%
0.44
Cash Flow From Continuing Operating Activities
-11.90
-25.02%
-9.52
-78.15%
-5.34
-1316.63%
0.44
Net Income From Continuing Operations
-16.45
-2592.27%
0.66
+107.78%
-8.48
-74.98%
-4.85
Depreciation Amortization Depletion
4.22
+33.08%
3.17
+145.67%
1.29
-3.00%
1.33
Depreciation And Amortization
4.22
+33.08%
3.17
+145.67%
1.29
-3.00%
1.33
Other Non Cash Items
0.50
+104.39%
-11.29
-4864.56%
0.24
+51.92%
0.16
Stock Based Compensation
4.12
+50.31%
2.74
+11.16%
2.46
+11.54%
2.21
Provisionand Write Offof Assets
1.31
+53.16%
0.85
-58.44%
2.06
+132.47%
0.88
Deferred Tax
0.02
+101.10%
-1.90
0.00
—
Deferred Income Tax
0.02
+101.10%
-1.90
0.00
—
Operating Gains Losses
-0.26
-129.57%
-0.12
-23.66%
-0.09
-8.14%
-0.09
Gain Loss On Sale Of PPE
-0.26
-129.57%
-0.12
-23.66%
-0.09
-8.14%
-0.09
Change In Working Capital
-5.35
-47.19%
-3.63
-29.28%
-2.81
-454.48%
0.79
Change In Receivables
-0.76
+91.36%
-8.74
-121.67%
-3.94
-1135.42%
-0.32
Changes In Account Receivables
-0.76
+91.36%
-8.74
-121.67%
-3.94
-1135.42%
-0.32
Change In Inventory
-2.49
-32.24%
-1.89
-63.72%
-1.15
-143.90%
2.62
Change In Prepaid Assets
-0.22
-199.09%
0.22
-15.71%
0.26
+489.55%
-0.07
Change In Payables And Accrued Expense
-1.88
-127.81%
6.77
+234.88%
2.02
+239.86%
-1.45
Change In Accrued Expense
-2.92
-176.95%
3.79
+230.54%
1.15
+202.96%
-1.11
Change In Payable
1.03
-65.34%
2.98
+240.57%
0.88
+363.55%
-0.33
Change In Account Payable
1.03
-65.34%
2.98
+240.57%
0.88
+363.55%
-0.33
Investing Cash Flow
-3.73
+84.95%
-24.78
-1489.74%
-1.56
+17.51%
-1.89
Cash Flow From Continuing Investing Activities
-3.73
+84.95%
-24.78
-1489.74%
-1.56
+17.51%
-1.89
Net PPE Purchase And Sale
-3.73
-191.18%
-1.28
+17.83%
-1.56
+17.51%
-1.89
Purchase Of PPE
-4.11
-182.49%
-1.46
+17.46%
-1.76
+16.60%
-2.12
Sale Of PPE
0.38
+118.86%
0.17
-14.63%
0.20
-8.89%
0.23
Capital Expenditure
-4.11
-182.49%
-1.46
+17.46%
-1.76
+16.60%
-2.12
Net Business Purchase And Sale
0.00
+100.00%
-23.50
0.00
—
Purchase Of Business
0.00
+100.00%
-23.50
0.00
—
Financing Cash Flow
16.07
-18.37%
19.69
+118.30%
9.02
-48.45%
17.50
Cash Flow From Continuing Financing Activities
16.07
-18.37%
19.69
+118.30%
9.02
-48.45%
17.50
Net Issuance Payments Of Debt
12.43
+101.18%
6.18
+2223.71%
-0.29
+50.84%
-0.59
Issuance Of Debt
117.64
+41.36%
83.22
+53.46%
54.23
+49.14%
36.36
Repayment Of Debt
-105.21
-36.56%
-77.04
-41.30%
-54.52
-47.54%
-36.95
Long Term Debt Issuance
5.00
+0.00%
5.00
0.00
—
Long Term Debt Payments
-0.07
-3.17%
-0.06
-26.00%
-0.05
+89.15%
-0.46
Net Long Term Debt Issuance
4.93
-0.04%
4.94
+9974.00%
-0.05
+89.15%
-0.46
Short Term Debt Issuance
112.64
+44.01%
78.22
+44.24%
54.23
+49.14%
36.36
Short Term Debt Payments
-105.14
-36.59%
-76.98
-41.32%
-54.47
-49.27%
-36.49
Net Short Term Debt Issuance
7.50
+503.22%
1.24
+615.77%
-0.24
-83.97%
-0.13
Net Common Stock Issuance
4.46
-68.20%
14.01
+50.48%
9.31
-49.47%
18.43
Proceeds From Stock Option Exercised
0.01
0.00
—
0.00
Net Other Financing Charges
-0.83
-65.80%
-0.50
—
-0.34
Changes In Cash
0.45
+103.06%
-14.61
-789.06%
2.12
-86.79%
16.05
Effect Of Exchange Rate Changes
-0.15
-720.83%
0.02
0.00
—
Beginning Cash Position
5.92
-71.12%
20.51
+11.53%
18.39
+685.43%
2.34
End Cash Position
6.22
+5.03%
5.92
-71.12%
20.51
+11.53%
18.39
Free Cash Flow
-16.01
-45.92%
-10.97
-54.41%
-7.11
-323.93%
-1.68
Interest Paid Supplemental Data
3.64
+42.55%
2.55
+75.52%
1.45
+71.87%
0.85
Common Stock Issuance
4.46
-68.20%
14.01
+50.48%
9.31
-49.47%
18.43
Issuance Of Capital Stock
4.46
-68.20%
14.01
+50.48%
9.31
-49.47%
18.43
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category